$CGEN

Stifel reiterated a Buy rating and $4.00 price target on Compugen (CGEN) after its investor event, citing a 73% upside potential. The event focused on the MAIA-ovarian trial and expanded UnigenX platform. Compugen reported Q2 revenue of $2.6M, a net loss of $7.0M, and a strong cash position. H.C. Wainwright also maintained a Buy rating with a $4.00 target.

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Compugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.

Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45–9:25 AM ET. A live webcast and replay will be available on the company’s investor relations website. This follows several positive corporate updates, including strong 2025 financial results, an extended cash runway, and a royalty monetization deal with AstraZeneca.

Compugen has secured non-dilutive funding from AstraZeneca for rilvegostomig royalties, bolstering its financial stability and extending its cash runway into 2029. The company, rated a 'Buy,' is advancing its pipeline with key catalysts including the phase 3 MAIA-Ovarian cancer trial for COM701 and the phase 1 anti-IL18BP antibody GS-0321. Potential milestone payments of up to $1 billion from AstraZeneca and Gilead, along with mid-single-digit royalties, offer significant future upside.

Compugen Ltd. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. Management will hold fireside chats and 1x1 meetings at both virtual and in-person events. Live webcasts of the fireside chats will be available on Compugen's investor relations website, with replays accessible afterward.

RICHMOND HILL, ON, Oct. 27, 2025 /CNW/ -- Compugen Inc., the largest Canadian-owned Technology Ally, is excited to announce the successful award of all technology categories under the Supply Ontario End-User Computing Devices and Services Vendor of Record ( VOR ) Arrangement ( Tender #20172 ) .